News | May 8, 2024

MilliporeSigma Expands Its Optimized VirusExpress® Platform For Lentiviral Vectors, Further Enhancing Quality And De-Risking Cell And Gene Therapy Manufacturing

  • Simplifies and de-risks viral vector production with off-the-shelf lentivirus plasmids
  • Delivers a high-quality and performance solution for viral vector manufacturing
  • Reduces development timelines and costs

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, is pleased to announce the expansion of its VirusExpress® platform used in the development and manufacturing of lentiviral vectors. The platform now includes off-the-shelf packaging plasmids and GOI plasmid services to support a comprehensive, de-risked, high-quality solution for the development and manufacturing of gene therapies.

Leveraging experience, knowledge, and expertise from three decades of viral vector development and manufacturing, the fully optimized approach has already been used to accelerate production and seamlessly scale-up lentiviral-based gene therapy programs through IND-submission and into clinical trials.

Providing a lentivirus plasmid solution in conjunction with a fully optimized, scalable platform process and extensive analytics portfolio allows cell and gene therapy innovators to benefit from a comprehensive approach that offers a simplified, de-risked, and efficient path to GMP manufacturing.  In addition, the platform delivers the performance and product quality needed at a lower cost per therapeutic dose as cell and gene therapy transitions from development into clinical and commercial manufacturing.

MilliporeSigma is a leading viral vector CDMO and has been involved in this space since clinical trials for gene therapy began in the 1990s. As part of Millipore® CTDMO Services, it offers end-to-end, streamlined solutions for viral vector development and manufacturing to advance cell and gene therapies at its FDA- and EMA-inspected facilities in Carlsbad, California. The state-of-the-art, flexible facilities house upstream and downstream production suites, along with fill/finish, warehousing, QC labs, in addition to process and analytical labs to support early phase development to commercial manufacturing of suspension and adherent-based cell and gene therapy platforms.

Learn more about the VirusExpress® LV Platform

Source: MilliporeSigma